Exploring metabolic dysfunction in chronic kidney disease

被引:95
|
作者
Slee, Adrian D. [1 ]
机构
[1] Lincoln Univ, Sch Life Sci, Lincoln, England
关键词
Chronic kidney disease; Cachexia; Cardiovascular disease; STAGE RENAL-DISEASE; RENIN-ANGIOTENSIN SYSTEM; C-REACTIVE PROTEIN; LEAN BODY-MASS; GLOMERULAR-FILTRATION-RATE; PLASMA GHRELIN LEVELS; WORKING GROUP-REPORT; GROWTH-FACTOR-I; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE;
D O I
10.1186/1743-7075-9-36
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Impaired kidney function and chronic kidney disease (CKD) leading to kidney failure and end-stage renal disease (ESRD) is a serious medical condition associated with increased morbidity, mortality, and in particular cardiovascular disease (CVD) risk. CKD is associated with multiple physiological and metabolic disturbances, including hypertension, dyslipidemia and the anorexia-cachexia syndrome which are linked to poor outcomes. Specific hormonal, inflammatory, and nutritional-metabolic factors may play key roles in CKD development and pathogenesis. These include raised proinflammatory cytokines, such as interleukin-1 and -6, tumor necrosis factor, altered hepatic acute phase proteins, including reduced albumin, increased C-reactive protein, and perturbations in normal anabolic hormone responses with reduced growth hormone-insulin-like growth factor-1 axis activity. Others include hyperactivation of the renin-angiotensin aldosterone system (RAAS), with angiotensin II and aldosterone implicated in hypertension and the promotion of insulin resistance, and subsequent pharmacological blockade shown to improve blood pressure, metabolic control and offer reno-protective effects. Abnormal adipocytokine levels including leptin and adiponectin may further promote the insulin resistant, and proinflammatory state in CKD. Ghrelin may be also implicated and controversial studies suggest activities may be reduced in human CKD, and may provide a rationale for administration of acyl-ghrelin. Poor vitamin D status has also been associated with patient outcome and CVD risk and may indicate a role for supplementation. Glucocorticoid activities traditionally known for their involvement in the pathogenesis of a number of disease states are increased and may be implicated in CKD-associated hypertension, insulin resistance, diabetes risk and cachexia, both directly and indirectly through effects on other systems including activation of the mineralcorticoid receptor. Insight into the multiple factors altered in CKD may provide useful information on disease pathogenesis, clinical assessment and treatment rationale such as potential pharmacological, nutritional and exercise therapies.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Exploring metabolic dysfunction in chronic kidney disease
    Adrian D Slee
    Nutrition & Metabolism, 9
  • [2] Mitochondrial Dysfunction and Metabolic Reprogramming in Chronic Kidney Disease
    Li, Ying
    Hai Pham
    Singh, Prabhleen
    FASEB JOURNAL, 2019, 33
  • [3] Cerebral metabolic alterations and cognitive dysfunction in chronic kidney disease
    Tryc, Anita Blanka
    Alwan, Gueldan
    Bokemeyer, Martin
    Goldbecker, Annemarie
    Hecker, Hartmut
    Haubitz, Marion
    Weissenborn, Karin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (08) : 2635 - U1980
  • [4] Chronic Metabolic Acidosis in Chronic Kidney Disease
    Patschan, Daniel
    Patschan, Susann
    Ritter, Oliver
    KIDNEY & BLOOD PRESSURE RESEARCH, 2020, 45 (06): : 812 - 822
  • [5] Gonadal dysfunction in chronic kidney disease
    Palmer, Biff F.
    Clegg, Deborah J.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2017, 18 (01): : 117 - 130
  • [6] Diastolic dysfunction and chronic kidney disease
    Cho, Goo-Yeong
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2013, 28 (01): : 22 - 24
  • [7] BAROREFLEX DYSFUNCTION IN CHRONIC KIDNEY DISEASE
    Maranduca, Minela Aida
    Cojocaru, Elena
    Serban, Ionela-Lacramioara
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (03): : 639 - 643
  • [8] COGNITIVE DYSFUNCTION IN CHRONIC KIDNEY DISEASE
    Karasavvidou, Despina P.
    Makridis, Dimitrios E.
    Skoularopoulou, Maria N.
    Katsinas, Christos D.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 118 - 118
  • [9] Gonadal dysfunction in chronic kidney disease
    Biff F. Palmer
    Deborah J. Clegg
    Reviews in Endocrine and Metabolic Disorders, 2017, 18 : 117 - 130
  • [10] Metabolic bone disease in chronic kidney disease
    Martin, Kevin J.
    Gonzalez, Esther A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (03): : 875 - 885